XSHE
300639
Market cap597mUSD
Oct 09, Last price
6.27CNY
1D
1.29%
1Q
19.89%
IPO
45.45%
Name
Guangdong Hybribio Biotech Co Ltd
Chart & performance
P/E
—
P/S
6.09
EPS
—
Div yield, %
1.05%
Shrs. gr., 5y
-0.97%
Rev. gr., 5y
-24.28%
Revenues
665m
-18.44%
Net income
-131m
L-80.01%
CFO
344m
+336.48%
Dividend
May 23, 20240.065 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.
Key people
Weixiong Huang
Vice Chairman of the Board · since 2022
Qinghui Li
Chief Financial Officer · since 2014
Jianyu Wang
General Manager, Director · since 2022
Zhisheng Guan
Executive Deputy General Manager, Director · since 2022
Danrong Weng
Deputy General Manager
Xiaochuan Li
Chief Medical Officer · since 2023
Yi Chen
Deputy General Manager, Secretary of the Board · since 2017
Qiaozhong Guan
Chairman of the Board · since 2022
Longxu Xie
Staff Elected Director · since 2025
Xiaoyan Yang
Director · since 2010
Yingshi Chen
Independent Director
Youlin Qiao
Independent Director
Chunxue Yang
Independent Director
Headquarters & legal address
潮州市经济开发试验区北片高新区D5-3-3-4小区
潮州市, GD 521000
CN
潮州市, GD 521000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||